Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes

Canagliflozin (CANA) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with blood glucose lowering effects. CANA also promotes kidney protection in patients with cardiovascular diseases and type 2 diabetes (T2D), as well as in normoglycemic patients with hypertension or heart failure. Clinical s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2023-12, Vol.18 (12), p.e0295284-e0295284
Hauptverfasser:	Trentin-Sonoda, Mayra, Cheff, Véronique, Gutsol, Alex, Hébert, Richard L
Format:	Artikel
Sprache:	eng
Schlagworte:	Albumin Animals Antidiabetics Biochemistry Blood pressure Blood sugar Canagliflozin - pharmacology Canagliflozin - therapeutic use Cardiovascular diseases Care and treatment Congestive heart failure Creatinine Dapagliflozin Diabetes Diabetes mellitus (insulin dependent) Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 1 - complications Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 2 Diagnosis Diet Electrolytes Female Females Fibrosis Glucose Humans Hyperglycemia Hypertension Hypertension - complications Hypertension - drug therapy Kidney Kidney diseases Kidneys Lesions Male Males Medical research Medicine, Experimental Metabolism Mice Mortality Patient outcomes Sex Sodium Sodium citrate Sodium-glucose cotransporter Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Type 1 diabetes Type 2 diabetes Urine Water intake Water intakes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!